CSFB Lowers Earnings Estimates for Merck

Analyst Ken Kulju says the removal of Vioxx represents annual sales reduction of about $2.8 billion to $3 billion per year

CSFB cut its earnings estimates and price target for Merck (MRK ) after the drug maker recalled its arthritis drug Vioxx. CSFB has an underperform rating on the stock.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.